After billions in deals, Insilico CEO promises: ‘You haven't seen anything yet’
CompaniesInsilico MedicineEli LillyTakedaExelixisBoehringer IngelheimSK Biopharmaceuticals
Signals
Every pharma-relevant, de-duplicated event surfaced so far, primary source first. Client-scoped signals are never shown here.
Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset
CompaniesMereo BioPharmaSentynl TherapeuticsZydus LifesciencesAssetsalvelestatDiseasesalpha-1 antitrypsin deficiency-associated lung disease (AATD-LD)
2026 IPO stock tracker: How newly public biotechs are performing
Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale
CompaniesPTC TherapeuticsSangamo TherapeuticsAssetsST-920isaralgagene civaparvovecDiseasesFabry disease
Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100M
CompaniesZealand PharmaRoyalty PharmaProtagonist TherapeuticsTakedaAssetsrusfertideDiseasespolycythemia vera
Rebounding biotech funds expected to spur CDMO growth within year
LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drug
CompaniesLEO PharmaTanabe PharmaAssetsdersimelagonDiseaseserythropoietic protoporphyriaX-linked protoporphyria
Sandoz targets industry patent void with $322m Henlius deal
CompaniesSandozHenliusAssetscetuximabevolocumabbelimumabDiseasescolorectal cancersquamous cell carcinomalupus
Takeda’s narcolepsy nod opens orexin doors
CompaniesTakedaAssetsOrzeyfuloveporextonDiseasesnarcolepsy type 1
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
CompaniesReplimuneBristol Myers SquibbAssetsvusolimogene oderparepvec-wtpgnivolumabDiseasesunresectable advanced cutaneous melanoma
All eyes on psychedelic drugmakers as Definium, Compass near major catalysts
CompaniesDefinium TherapeuticsCompass PathwaysAssetsDT120COMP360Diseasesgeneralized anxiety disordermajor depressive disorderpost-traumatic stress disordertreatment-resistant depression
Scholar Rock rejigs approval filing after FDA flags violations at Novo plant
CompaniesScholar RockNovo NordiskAssetsapitegromabDiseasesspinal muscular atrophy
FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issues
CompaniesITM Isotope TechnologiesNovartisAssets177Lu-edotreotideITM-11everolimusDiseasesgastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
CompaniesReplimuneEli LillyNovo NordiskAssetsRP1TudriqevFoundayoWegovyretatrutideDiseasesadvanced melanoma
Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
CompaniesTaiho PharmaceuticalCullinan TherapeuticsAssetszipalertinibDiseasesadvanced non-small cell lung cancer
Nascent US psychedelic therapy opportunity attracts overseas manufacturers
CompaniesBLS PharmaceuticalsOptimi HealthEli LillyAtaiBeckleyAssetsMDMApsilocybinDiseasesserious mental illnesspost-traumatic stress disordertreatment-resistant depression
Capricor soars on potential FDA review extension, filing amendments
CompaniesCapricor TherapeuticsAssetsderamiocelDiseasesDuchenne muscular dystrophy
Patients comfortable with AI-created portal messages
‘Considerable’ progress made in cancer mortality disparities
Diseasescancer
Standards target cognitive care in sickle cell disease
Diseasessickle cell disease